Severe eosinophilic asthma: a roadmap to consensus.

Journal article

Asthma is widely accepted as a complex heterogeneous condition with diverse pathophysiological mechanisms, clinical presentations, comorbidities, physiological characteristics, pathology and outcomes that is typically best managed by a multidisciplinary team [1–4]. Severe asthma is recognised as a major unmet need with a high personal and social impact, as well as a high burden on healthcare resources [4]. As a consequence of advances in the development of precision medicines for patients with severe asthma, the need to identify asthma subtypes by phenotype based on clinical, functional or inflammatory parameters is becoming a mandatory part of management [4–6].
Severe eosinophilic asthma (SEA), also referred to as severe asthma with eosinophilia, is yet to be clearly defined and warrants further discussion.
A task force has identified key consensus issues for defining, diagnosing and treating severe eosinophilic asthma.

Authors: Buhl, R; Humbert, M; Bjermer, L; Chanez, P; Heaney, L

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: European Respiratory Society
• Journal: European Respiratory Journal
• Volume: 49
• Issue: 5
• Pages: 1700634
• Publication date: 2017-05-01
• Acceptance date: 2017-03-27
• DOI: 10.1183/13993003.00634-2017
• ISSN: 1399-3003
• Language: English
• Keywords: Editorial